The boom of Viagra initially ignited significant progress in the drug sector, creating a perception of substantial returns. However, funding in companies solely reliant on blockbuster drugs like the erectile dysfunction pill presents substantial dangers. Intellectual property expiry has resulted

The recent surge in funding into niche pharmaceutical companies, particularly those focusing on novel therapies and complex drug development programs, has fueled what some are calling "High Roller Pharma." While the possibility for blockbuster treatments and significant returns is certain, the as